Journal issues
Contents
Free online sample copy
E-mail alert
Register
Search

Editorial
Editor
Instructions to authors
Scope
Audience
Related journals
Citation
Indexed in

Customer services
Subscribe
Order sample copy
Reprint request
Permissions
Contacts
News
Help

Journal home

Lupus

LUPUS Special Issue – Accelerated Atheroma

Lupus is the only journal devoted exclusively to lupus research, bringing together clinical and laboratory-based studies on the disease and its many clinical manifestations.

Read by medical specialists worldwide, Lupus brings you ground-breaking studies from leading specialists in every lupus-related discipline. This special issue further enhances Lupus as the journal with the best reputation for the latest cutting-edge research.

About the Accelerated Atheroma Special Issue
The spotlight on pathogenetic mechanisms in atheroma has moved from cholesterol and lipids, through inflammation, and almost inevitably onto immunology.

A major impetus to the understanding of immunological involvement in atherogenesis has come from studies in two related diseases – lupus and the antiphospholipid (Hughes) Syndrome.

The incidence of coronary events in lupus has been reported to be increased by a factor of up to 50-fold. To the traditional factors – steroid therapy, nephrotic syndrome, hyperlipidaemia and chronic inflammation – the presence of antiphospholipid antibodies comes as an important, possibly even pivotal, addition.

In 1983, this new link was established with the description of the antiphospholipid syndrome (APS) – a prothrombotic disorder leading not only to venous and to arterial thrombosis, but in some patients, to accelerated vascular disease, strokes and early heart attacks.

The clinical links between APS and accelerated arterial disease were strengthened by the observation that some antiphospholipid antibodies cross-reacted with oxidised low-density lipoproteins (ox-LDL). This finding led to the development of new assays and to a new understanding of the immunogenicity of ox-LDL and its uptake into macrophages and foam cells.

So, atheroma is moving into new areas. We have, for example, already in place, straightforward immunoassays which may provide precise prognostic data.

In this special issue of Lupus, the leading researchers in this new area have contributed to a unique and succinct update. These studies mark a turning point in the study of accelerated arterial disease – all brought to you in this landmark special issue.

Graham Hughes
Editor, Lupus

How to obtain your own copy
This special issue will be published in March 2000 and a copy can be yours for only £25/US$40.

For further information and to order a copy of this dedicated special issue, please contact:
Sharon Marshall, Marketing Manager, Specialist Journals, Nature Publishing Group, Houndmills, Basingstoke, Hants. RG21 6XS. England
Tel: +44 (0) 1256 302857 Fax: +44 (0) 1256 328339 Email: s.marshall@nature.com

Back to news list